Esin YILDIZ, Emrah UĞUZ, Öcal BERKAN, Gökhan ÖZERDEM, Mete HIDIROĞLU

The proinflammatory cytokine-mediated protective effects of pentoxifylline, iloprost, and cilostazol on a mitigating lung injury induced by lower limb ischemia and reperfusion in rats

Amaç: Bu çalışmada, pentoksifilin, iloprost ve silostazolün alt ekstremite iskemisi-reperfüzyonu ile tetiklenen akut akciğer hasarını azaltıp azaltmadığı ve bu koruyucu etkilere sitokinlerin dahil olup olmadığı araştırıldı.Çalışma planı: Kırk sıçan rastgele beş gruba ayrıldı: kontrol (grup 1), iskemi-reperfüzyon (grup 2), pentoksifilin (grup 3), iloprost (grup 4), iloprost ve silostazol (grup 5). Tüm ilaçlar iskemi öncesi uygulandı. Tümör nekroz faktör-alfa (TNF-a), interlökin-6 (IL-6) ve total sialik asit (TSA) incelemeleri için numuneler alındı. Akciğer hasarı bulguları incelendi.Bul gu lar: İnterlökin-6 ve TNF düzeylerinde 90. dakikada artış olduğu ve hatta 240. dakikadan sonra da yüksek seyrettiği saptandı. Grup 3 ve 4'de, IL-6 ve TNF düzeyleri, grup 2 ile karşılaştırıldığında 90, 180. ve 240. dakikalarda anlamlı olarak düşüktü. Total sialik asit düzeyleri 180. dakikada grup 2, 3, 4 ve 5'te bazal ve 90. dakikadaki değerlerden anlamlı olarak farklı idi. Bu zaman noktasında TSA düzeyleri grup 2 ve 3'te grup 4 ve 5 ile karşılaştırıldığında anlamlı derecede yüksekti.So nuç: Alt ekstremite İ/R ile tetiklenmiş bu akut akciğer hasarı modelinde, pentoksifilin, iloprost ve silostazol ile ön tedavinin uygulanması, proinflamatuvar aktiviteyi ve parankimal akciğer hasarını anlamlı düzeyde azaltmıştır

Sıçanlarda alt ekstremite iskemisi ve reperfüzyonu ile tetiklenen akciğer hasarının azaltılmasında pentoksifilin, iloprost ve silostazolün proenflamatuvar sitokin aracılı koruyucu etkileri

Background: This study aims to elucidate whether pentoxifylline, iloprost and cilostazol mitigates acute lung injury induced by lower limb ischemia-reperfusion (I/R) and their protective effects cover cytokines. Methods: Forty rats were randomized into five groups: control (group 1), ischemia-reperfusion (group 2), pentoxifylline (group 3), iloprost (group 4), iloprost and cilostazol (group 5). All drugs were administered before ischemia. Samples were obtained for tumor necrosis factor- alpha (TNF-a), interleukin 6 (IL-6), and total sialic acid (TSA) assays. Findings of lung injury were examined. Results: Interleukin-6 and TNF levels were increased at 90 minutes and sustained elevated even after 240 minutes. In groups 3 and 4, IL-6 and TNF levels were significantly lower at 90, 180 and 240 minutes compared to group 2. At 180 minutes, TSA levels in groups 2, 3, 4 and 5 were significantly different from baseline and 90 minute levels. At this time point, TSA levels of group 2 and 3 were significantly higher compared to group 4 and 5. Conclusion: In this acute lung injury model induced by I/R of the lower limbs, pretreatment with pentoxifylline, iloprost and cilostazol significantly attenuated pro- inflammatory activities and parenchymal lung damage

PDF

___

1. Welbourn R, Goldman G, O’Riordain M, Lindsay TF, Paterson IS, Kobzik L, et al. Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia. J Appl Physiol (1985) 1991;70:2645-9.
2. Tassiopoulos AK, Carlin RE, Gao Y, Pedoto A, Finck CM, Landas SK, et al. Role of nitric oxide and tumor necrosis factor on lung injury caused by ischemia/reperfusion of the lower extremities. J Vasc Surg 1997;26:647-56.
3. Seekamp A, Warren JS, Remick DG, Till GO, Ward PA. Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol 1993;143:453-63.
4. Berkan O, Göl MK, Içağasioğlu S, Cetnkaya O, Yildiz E, Doğan K, et al. Sialic acid is a marker of lung injury following lower extremities ischemia/reperfusion. Eur J Vasc Endovasc Surg 2004;27:553-8.
5. Anner H, Kaufman RP Jr, Valeri CR, Shepro D, Hechtman HB. Reperfusion of ischemic lower limbs increases pulmonary microvascular permeability. J Trauma 1988;28:607-10.
6. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
7. Lessa A, Suguihara C, Xianyu S, Hehre D, Devia C, Bancalari E. The effect of pentoxifylline on the pulmonary response to high tidal volume ventilation in rats. Pulm Pharmacol Ther 2008;21:54-60.
8. Iyú D, Glenn JR, White AE, Johnson AJ, Fox SC, Heptinstall S. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function. Platelets 2010;21:329-42.
9. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889-924.
10. Koksel O, Ozdulger A, Aytacoglu B, Tamer L, Polat A, Sucu N, et al. The influence of iloprost on acute lung injury induced by hind limb ischemia-reperfusion in rats. Pulm Pharmacol Ther 2005;18:235-41.
11. Sahin MA, Onan B, Guler A, Oztas E, Uysal B, Arslan S, et al. Cilostazol, a type III phosphodiesterase inhibitor, reduces ischemia/reperfusion-induced spinal cord injury. Heart Surg Forum 2011;14:E171-7.
12. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-9.
13. Mazzone A, Faggioli P, Cusa C, Stefanin C, Rondena M, Morelli B. Effects of iloprost on adhesion molecules and F1 + 2 in peripheral ischemia. Eur J Clin Invest 2002;32:882-8.
14. Riva CM, Morganroth ML, Ljungman AG, Schoeneich SO, Marks RM, Todd RF 3rd, et al. Iloprost inhibits neutrophilinduced lung injury and neutrophil adherence to endothelial monolayers. Am J Respir Cell Mol Biol 1990;3:301-9.
15. Colletti LM, Cortis A, Lukacs N, Kunkel SL, Green M, Strieter RM. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophildependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998;10:182-91.
16. Pararajasingam R, Weight SC, Bell PR, Nicholson ML, Sayers RD. Pulmonary nitric oxide metabolism following infrarenal aortic cross-clamp-induced ischaemia-reperfusion injury. Eur J Vasc Endovasc Surg 2000;19:47-51.
17. Horgan MJ, Palace GP, Everitt JE, Malik AB. TNF-alpha release in endotoxemia contributes to neutrophil-dependent pulmonary edema. Am J Physiol 1993;264:H1161-5.
18. Moore TM, Khimenko P, Adkins WK, Miyasaka M, Taylor AE. Adhesion molecules contribute to ischemia and reperfusion-induced injury in the isolated rat lung. J Appl Physiol (1985) 1995;78:2245-52.
19. Tassiopoulos AK, Hakim TS, Finck CM, Pedoto A, Hodell MG, Landas SK, et al. Neutrophil sequestration in the lung following acute aortic occlusion starts during ischaemia and can be attenuated by tumour necrosis factor and nitric oxide blockade. Eur J Vasc Endovasc Surg 1998;16:36-42.
20. Krishnadasan B, Naidu BV, Byrne K, Fraga C, Verrier ED, Mulligan MS. The role of proinflammatory cytokines in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2003;125:261-72.
21. Eppinger MJ, Deeb GM, Bolling SF, Ward PA. Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol 1997;150:1773-84.
22. Donnahoo KK, Shames BD, Harken AH, Meldrum DR. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999;162:196-203.
23. Knowles R, Keeping H, Graeber T, Nguyen K, Garner C, D’Amico R, et al. Cytokine control of PMN phagocytosis: regulatory effects of hypoxemia and hypoxemiareoxygenation. Am J Physiol 1997;272:C1352-64.
24. Gaines GC, Welborn MB 3rd, Moldawer LL, Huber TS, Harward TR, Seeger JM. Attenuation of skeletal muscle ischemia/reperfusion injury by inhibition of tumor necrosis factor. J Vasc Surg 1999;29:370-6.
25. Berkan O, Göl MK, Günay L, Sagaban M. Sialic acid is an indicator of inflammation due to cardiopulmonary bypass but not myocardial damage. J Cardiovasc Surg (Torino) 2002;43:489-93.
26. Chen X, Varki A. Advances in the biology and chemistry of sialic acids. ACS Chem Biol 2010;5:163-76.
27. Kamerling JP, Gerwig GJ. Structural analysis of naturally occurring sialic acids. Methods Mol Biol 2006;347:69-91.